BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 34715481)

  • 1. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
    Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
    J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis.
    Rocchi C; Forcadela M; Kelly P; Linaker S; Gibbons E; Bhojak M; Jacob A; Hamid S; Huda S
    Mult Scler; 2024 Mar; 30(3):345-356. PubMed ID: 38258822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder.
    Hu Y; Sun Q; Yi F; Yao L; Tian Y; Tang H; Luo M; Xie N; Wang Z; Liao X; Zhou L; Xu H; Zhou Y
    Front Immunol; 2022; 13():1056944. PubMed ID: 36569880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
    Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients.
    Lana-Peixoto MA; Talim NC; Callegaro D; Marques VD; Damasceno A; Becker J; Gonçalves MVM; Sato H;
    Mult Scler Relat Disord; 2023 Jul; 75():104730. PubMed ID: 37156036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
    Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
    Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.
    Edgar Patricio CD; Eleanor THG; Francisco José CZ; Gabriela ACM; Hyland AO; Fernando GL; María TA; Beatriz N; Marcos SD; Alfredo GPW
    Mult Scler Relat Disord; 2020 Sep; 44():102208. PubMed ID: 32562910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
    Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
    Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population.
    Mao Z; Yin J; Zhong X; Zhao Z; Qiu W; Lu Z; Hu X
    BMC Neurol; 2015 Sep; 15():160. PubMed ID: 26337073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.
    Carnero Contentti E; Daccach Marques V; Soto de Castillo I; Tkachuk V; Ariel B; Castillo MC; Cristiano E; Diégues Serva GB; Dos Santos AC; Finkelsteyn AM; López PA; Patrucco L; Molina O; Pettinicchi JP; Toneguzzo V; Caride A; Rojas JI
    J Neurol; 2020 May; 267(5):1260-1268. PubMed ID: 31932911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder in a paraneoplastic context.
    Hyun JW; Park NY; Kim MJ; Kim H; Kim KH; Kim SH; Kim HJ
    J Neurol Sci; 2023 Nov; 454():120825. PubMed ID: 37813018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
    Wang L; Du L; Li Q; Li F; Wang B; Zhao Y; Meng Q; Li W; Pan J; Xia J; Wu S; Yang J; Li H; Ma J; ZhangBao J; Huang W; Chang X; Tan H; Yu J; Zhou L; Lu C; Wang M; Dong Q; Lu J; Zhao C; Quan C
    Front Immunol; 2022; 13():873576. PubMed ID: 35432315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus.
    Sepulveda M; Delgado-García G; Blanco Y; Sola-Valls N; Martinez-Lapiscina EH; Armangué T; Montejo C; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Escudero D; Ruiz-García R; Llufriu S; Dalmau J; Graus F; Saiz A
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31471461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders.
    Camera V; Messina S; Elhadd KT; Sanpera-Iglesias J; Mariano R; Hacohen Y; Dobson R; Meletti S; Wassmer E; Lim MJ; Huda S; Hemingway C; Leite MI; Ramdas S; Palace J
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):101-111. PubMed ID: 34583946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very late onset neuromyelitis optica spectrum disorders.
    Nakahara K; Nakane S; Nagaishi A; Narita T; Matsuo H; Ando Y
    Eur J Neurol; 2021 Aug; 28(8):2574-2581. PubMed ID: 33960076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
    Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
    Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.